Shanghai Junshi Biosciences Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.85%

Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Junshi Biosciences Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥600.81 Million
≈ $87.92 Million USD Cash + Short-term Investments

Total Assets

CN¥12.38 Billion
≈ $1.81 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Junshi Biosciences Co Ltd asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688180 liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥600.81 Million 4.85%
Total Liquid Assets CN¥600.81 Million 4.85%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.85% CN¥600.81 Million
≈ $87.92 Million
CN¥12.38 Billion
≈ $1.81 Billion
+0.87pp
2024-12-31 3.99% CN¥430.51 Million
≈ $63.00 Million
CN¥10.80 Billion
≈ $1.58 Billion
+3.99pp
2020-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥8.01 Billion
≈ $1.17 Billion
0.00pp
2019-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥4.42 Billion
≈ $647.14 Million
-0.13pp
2018-12-31 0.13% CN¥5.52 Million
≈ $807.16K
CN¥4.26 Billion
≈ $622.98 Million
-11.96pp
2017-12-31 12.09% CN¥147.43 Million
≈ $21.57 Million
CN¥1.22 Billion
≈ $178.48 Million
-20.42pp
2016-12-31 32.50% CN¥373.47 Million
≈ $54.65 Million
CN¥1.15 Billion
≈ $168.14 Million
-38.21pp
2014-12-31 70.71% CN¥235.44 Million
≈ $34.45 Million
CN¥332.94 Million
≈ $48.72 Million
--
pp = percentage points

About Shanghai Junshi Biosciences Co Ltd

SHG:688180 China Biotechnology
Market Cap
$3.61 Billion
CN¥24.67 Billion CNY
Market Cap Rank
#4386 Global
#682 in China
Share Price
CN¥32.22
Change (1 day)
-0.86%
52-Week Range
CN¥28.93 - CN¥45.73
All Time High
CN¥151.00
About

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more